Skip to main content

Search

Choose Location

International
Americas
Asia Pacific
Europe
Middle East & Africa

: Global | English
: Novartis Foundation | English

: Argentina | Español
: Brazil | Português
: Canada | English
: Canada | Français
: Central America | Español
: Colombia | Español
: Mexico | Español
: United States | English

: Australia | English
: Bangladesh | English
: Hong Kong S.A.R. | 繁體中文
: India | English
: Indonesia | English
: Japan | 日本語
: Korea | 한국어
: Mainland China | 中文
: Malaysia | English
: Pakistan | English
: Philippines | English
: Singapore | English
: Taiwan | 繁體中文
: Thailand | ภาษาไทย

: Austria | Deutsch
: Belgium | Français
: Belgium | Nederlands
: Bulgaria | Български
: Czech Republic | Česky
: Czech Republic | English
: Denmark | Dansk
: Estonia | Eesti
: Finland | Suomalainen
: France | Français
: Germany | Deutsch
: Greece | Ελληνικά
: Hungary | Magyar
: Ireland | English
: Italy | Italiano
: Latvia | Latvian
: Lithuania | Lithuanian
: Netherlands | Nederlands
: Norway | Norsk
: Poland | Polski
: Portugal | Português
: Romania | Română
: Russia | Русский
: Serbia | Srpski
: Slovakia | Slovensky
: Slovenia | Slovenščina
: Slovenia | English
: Spain | Español
: Sweden | Svenska
: Switzerland | Deutsch
: Switzerland | Français
: Türkiye | Türkçe
: United Kingdom | English

: Egypt | English
: Israel | עברית
: Saudi Arabia | العربية
: South Africa | English

Choose Location

International Americas Asia Pacific Europe Middle East & Africa

: Argentina | Español
: Australia | English
: Austria | Deutsch
: Bangladesh | English
: Belgium | Français
: Belgium | Nederlands
: Brazil | Português
: Bulgaria | Български
: Canada | English
: Canada | Français
: Central America | Español
: Colombia | Español
: Czech Republic | Česky
: Czech Republic | English
: Denmark | Dansk
: Egypt | English
: Estonia | Eesti
: Finland | Suomalainen
: France | Français
: Germany | Deutsch
: Greece | Ελληνικά
: Hong Kong S.A.R. | 繁體中文
: Hungary | Magyar
: India | English
: Indonesia | English
: Ireland | English
: Israel | עברית
: Italy | Italiano
: Japan | 日本語
: Korea | 한국어
: Latvia | Latvian
: Lithuania | Lithuanian
: Mainland China | 中文
: Malaysia | English
: Mexico | Español
: Netherlands | Nederlands
: Norway | Norsk
: Global | English
: Novartis Foundation | English
: Pakistan | English
: Philippines | English
: Poland | Polski
: Portugal | Português
: Romania | Română
: Russia | Русский
: Saudi Arabia | العربية
: Serbia | Srpski
: Singapore | English
: Slovakia | Slovensky
: Slovenia | Slovenščina
: Slovenia | English
: South Africa | English
: Spain | Español
: Sweden | Svenska
: Switzerland | Deutsch
: Switzerland | Français
: Taiwan | 繁體中文
: Thailand | ภาษาไทย
: Türkiye | Türkçe
: United Kingdom | English
: United States | English

About

Board of Directors

Joerg Reinhardt

Simon Moroney

Nancy C. Andrews

Ton Buechner

Patrice Bula

Elizabeth (Liz) Doherty

Ana de Pro Gonzalo

Bridgette Heller

Daniel Hochstrasser

Frans van Houten

Charles L. Sawyers

William T. Winters

John D. Young

Charlotte Pamer-Wieser

Executive Committee

Vasant (Vas) Narasimhan

Shreeram Aradhye

Victor Bulto

Aharon (Ronny) Gal

Karen L. Hale

Patrick Horber

Harry Kirsch

Rob Kowalski

Steffen Lang

Fiona Marshall

Klaus Moosmayer

Lutz Hegemann

Kees Roks

Michelle Weese

Products

Therapeutic areas

Cardiovascular, renal and metabolic

Immunology

Neuroscience

Oncology

People and culture

Diversity, equity and inclusion

Equity

Inclusivity

Parental leave

Society

Novartis Gene Therapies

Manufacturing

Quality

Audit program

Novartis quality management system (QMS)

Product and patient safety training

Regulatory inspections

Product recalls

Third-party suppliers

Awards and recognition

Test Event - Country - State

About

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Patients and caregivers

Novartis commitment to patients and caregivers

Diseases

Patient organization funding

Patients perspectives stories

Patients and caregivers

Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

Healthcare professionals

Medical congresses and events

ASCO Annual Meeting

Products

Novartis pipeline

Managed access programs

Novartis Gene Therapies managed access program

Novartis external funding

Healthcare professional resources by country

Investigator-initiated trials / studies

Novartis medical information

Submit medical enquiry

Healthcare professionals

Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

Research and development

Technology platforms

Research disease areas

Cardiovascular and metabolic disease research at Novartis

DAx: exploratory disease research at Novartis

Global Health disease area research at Novartis

Immunology disease research at Novartis

Neuroscience research at Novartis

Oncology research at Novartis

Ophthalmology research at Novartis

Novartis pipeline

Research collaborations

Collaborations

Research & development

Discover how Novartis turns breakthrough science into transformative, high-value treatments.

ESG

Access

Creating sustainable business models

Value-based pricing

Sub-Saharan Africa

Donations

Novartis access principles

Novartis oncology access

Patents and licensing

Environmental sustainability

Climate

Waste

Water

Ethics, risk and compliance

Ethical behavior

Compliance

Human rights

Learning and engagement

Risk management

Global health

Pandemic preparedness

Avoidable blindness

Chagas disease

Leprosy

Malaria

Sickle cell disease (SCD)

Novartis Foundation

Diversity, equity and inclusion

ESG index

Reporting and transparency hub

Novartis in Society Integrated Report

ESG rating performance

Targets

Patient organization funding

Payments to healthcare professionals

Public policy

A living wage

A safe workplace

Animal research

Environmental, social and governance

Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

Investors

Event calendar

event with single session

test multiple session

Financial data

Novartis annual results

Novartis quarterly results

Novartis SEC filings

Product sales

Fixed-income securities

Expected currency impact

Share data and analysis

Share monitor

Dividend information

Share ownership

Share overview

Return on investment calculator

Shareholder information

General Meetings

American Depositary Receipts (ADR)

Share buyback

Frequently asked questions

Company overview

Corporate governance

Reporting and transparency hub

Novartis in Society Integrated Report

Reporting archive

ESG rating performance

Publications order form

ESG

test-event

Events with hcp

Investors

Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

News

News archive

Media library

Stories

Subscribe

News

Information for journalists including media releases, statements, stories, multimedia resources and more.

Careers

Career search

Our business functions

Careers in research and development

Careers in operations

Careers in commercial and sales

Careers in global functions

Why Novartis

Career hub

Temporary contracts

Early careers

Graduates

Students

US Biomedical Research internship programs

Community exploration and learning lab (CELL)

Careers

Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

Clinical trials

Partnering

Supplier portal

Report side effects

Contacts

New Event

test-physical
Home

Working together, we can reimagine medicine to improve and extend people’s lives.

Header

test

August 12, 2024 - September 12, 2024

Session 1 [With no country]
Session 2

August 20, 2024

09:07 - 09:07 CEST

Speakers

Speakers

Dummy Featured News Alt

The Senior Manager

Novartis Global Expertise

Lorem Ipsum Alt

Teste 2

Novartis Global Expertise

John

his field is limited to 255 characters.

August 29, 2024

10:26 - 10:26 CEST

Novartis

Working together

Patients and caregivers
Healthcare professionals
Researchers
Job seekers
Journalists
Investors

Topics

Q2 2024
Access
Diversity
ESG
SpeakUp

Explore

Pipeline
Products
Clinical trials
Partnering
Stories

Therapeutic areas

Cardiovascular, renal and metabolic
Immunology
Neuroscience
Oncology

Search

Footer Bottom

© 2024 Novartis AG

Terms of use
Privacy
Cookie settings
Contacts
Locations
Site map
Open source
Web accessibility

Novartis Site Directory

This site is intended for a global audience